| Target Price | $89.76 |
| Price | $86.75 |
| Potential |
3.47%
register free of charge
|
| Number of Estimates | 33 |
|
33 Analysts have issued a price target Edwards Lifesciences 2026 .
The average Edwards Lifesciences target price is $89.76.
This is
3.47%
register free of charge
$105.00
21.04%
register free of charge
$72.72
16.17%
register free of charge
|
|
| A rating was issued by 43 analysts: 28 Analysts recommend Edwards Lifesciences to buy, 15 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Edwards Lifesciences stock has an average upside potential 2026 of
3.47%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 5.44 | 6.20 |
| 8.57% | 13.96% | |
| EBITDA Margin | 30.06% | 29.62% |
| 9.12% | 1.47% | |
| Net Margin | 76.75% | 24.65% |
| 174.17% | 67.88% |
39 Analysts have issued a sales forecast Edwards Lifesciences 2025 . The average Edwards Lifesciences sales estimate is
This results in the following potential growth metrics:
28 Analysts have issued an Edwards Lifesciences EBITDA forecast 2025. The average Edwards Lifesciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
39 Edwards Lifesciences Analysts have issued a net profit forecast 2025. The average Edwards Lifesciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 6.96 | 2.63 |
| 202.61% | 62.21% | |
| P/E | 33.00 | |
| EV/Sales | 7.45 |
39 Analysts have issued a Edwards Lifesciences forecast for earnings per share. The average Edwards Lifesciences EPS is
This results in the following potential growth metrics and future valuations:
Edwards Lifesciences...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Truist Securities |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Truist Securities:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Oct 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


